212.3 ð©º å §ç§å°ç§èåç
212.3.0.1 1ïžâ£ HAV vs HEV Differential
| Feature | HAV | HEV |
|---|---|---|
| Family | Picornavirus | Hepevirus |
| Transmission | Fecal-oral | Fecal-oral, pork/wild boar, blood |
| Geographic | Worldwide | S Asia + Mexico + some EU |
| Severity | Usually mild; severe in older | Mild in healthy; severe in pregnant (20-30% mortality 3rd trimester) |
| Chronic | No | Rare in immunocompromise (Genotype 3) |
| Vaccine | Yes (HAVRIX, VAQTA) | Hepai 239 (China only) |
| Diagnosis | IgM anti-HAV | IgM anti-HEV / PCR |
212.3.0.2 2ïžâ£ Cholestatic + Relapsing Forms
- Cholestatic: prolonged jaundice + pruritus (months); UDCA for pruritus relief
- Relapsing: recurrent over 6-12 mo; self-limited eventually; doesnât progress to chronic
212.3.0.3 3ïžâ£ HAV in Immunocompromise
- Generally same outcome as healthy (acute, self-limited)
- Severe in chronic liver disease coinfection
- Reduced immunogenicity of vaccine (use 2-dose series + check titers)
212.3.0.4 4ïžâ£ Twinrix (HAV + HBV)
- Combination vaccine for travel + high-risk
- 3-dose series (0, 1, 6 mo) or accelerated (0, 7, 21 d + booster 12 mo)
- Efficient for travel medicine
212.3.0.5 5ïžâ£ HAV in Pregnancy
- Generally same outcome as non-pregnant
- Severe / fulminant rare but possible (vs HEV pregnancy)
- Vaccine safe in pregnancy if indicated
- Vertical transmission rare
212.3.0.6 6ïžâ£ Fulminant HAV Management
- Kingâs College criteria: INR > 6.5 OR (Bilirubin > 17.5 mg/dL + age > 40 + INR > 3.5)
- N-acetylcysteine â some benefit
- Liver transplant referral
212.3.0.7 7ïžâ£ 2017-2024 USA Outbreak Response
- CDC vaccination campaigns
- Outreach to homeless populations
- Harm reduction (syringe services, supervised use)
- Outbreak vaccination in shelters, drug treatment
- Sanitation improvement
- Surveillance